Tom Burt

Head of Life Sciences

2023 - Current

Partner

2017 - 2023

- Investments made into Limflow, MaxCyte, Redx Pharma, Sphere Fluidics & Synthace - Board member: Redx Pharma, SphereFluidics [Interim Chair] & Synthace [Interim Chair]

Senior Research Analyst [Healthcare & Life Sciences]

2015 - 2017

Stockbroking and advisory firm serving the UK small & mid-cap market Initiation/ Coverage included: Clinigen, PureTech, Electrical Geo, Abcam, ConvaTec

Investment Director

2013 - 2015

Late-venture/growth equity fund investing in EU Healthcare & Life sciences with c.EUR2bn AUM Responsibilities included: - Transaction Management - Investment Oversight/ Portfolio Assistance - Valuation Analysis - Commercial/Technical assessment of new investment opportunities Portfolio: Esaote/ Euromedic/ Santhera/ Stallergenes Examples of Completed Transactions include: Euromedic: concurrent sell-side auction (c. EUR 1bn) and minority s/h acquisition (09/2014). Re-financing (02/2013) and divestment of Czech labs (10/2013) Esaote: minority s/h acquisition (07/2014). Re-financing (07/2015)

Associate, Novo Growth Equity

2010 - 2013

Late-venture/growth equity division of Novo Holdings investing US$200m p.a in EU/US Healthcare & Life science companies Responsibilities included: - Valuation Analysis - Commercial Assessment - Due Diligence - Investment Oversight/ Portfolio Assistance / Business Development Examples of Completed Transactions include: - Archimedes Pharma Ltd: GBP 65m Series D Investment/ Warburg Pincus stake acquisition - Orexo AB: SEK 150m Secondary purchase/ SEK 111m Convertible loan/ SEK 250m Rights Iss. - Aerocrine AB:SEK 112m Directed Issue/ SEK 112m Convertible loan - Novo A/S DKK 4.1bn Secondary purchase in Chr.Hansen A/S/ US$700m Acquisition of Xellia Pharmaceuticals

Associate, Healthcare Investment Banking

2006 - 2010

European Healthcare/Life Science Investment Banking (M&A/ ECM/ DCM) Examples of Completed Transactions include: - ECM: Santhera CHF 100m IPO / TiGenix €46m IPO / Basilea CHF 324m Follow-on/ NicOx €129m Follow-on/ SkyePharma GBP 21.0m Placing - M&A: Biocompatibles- BrachySciences/ Parexel-ClinPhone/ Protherics-Macromed/ Lonza-Amaxa/ ProStrakan-Cellegy Assets/ BTG-Protherics

Research Engineer

2001 - 2005

DNA vaccine production/ scale-up